 |
Zavesca Inhibits the Synthesis
of Glycosphingolipid Substrate
|
| Inhibit.
. . . . . |
Zavesca
inhibits glucosylceramide synthase, the first enzyme
responsible for glycosphingolipid (GSL) synthesis.
|
| Reduce. . . .
. |
Zavesca reduces
the accumulation of GSL substrate.
|
| Improve. . . . . |
Zavesca improves
the ability of the residual glucocerebrosidase to catabolize
GSL substrate.
|
|
| Zavesca Helps Bring Balance to
GSL Metabolism |
Inhibited
GSL production relieves the deficient enzyme of excessive
substrate burden, thereby reducing the degree of GSL accumulation.
|
| Before
Treatment |
After
Treatment With Zavesca |
Glucosylceramide exceeds
capacity
of residual
glucocerebrosidase activity.
|
Reduced level
of glucosylceramide helps relieve the burden on the
residual glucocerebrosidase.
|
A Unique Approach to Treating a Rare Disease
|
